News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Harinder Gill: Arsenic Trioxide in newly-diagnosed Acute Promyelocytic Leukemia patients
Harinder Gill/X
Dec 24, 2024, 08:02

Harinder Gill: Arsenic Trioxide in newly-diagnosed Acute Promyelocytic Leukemia patients

Harinder Gill, Clinical Associate Professor in Haematology at HKU Medicine, shared a post on X:

“Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly-diagnosed patients: impact and outcome in Blood Advances of American Society of Hematology.”arsenic trioxide

Title: Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly-diagnosed patients: impact and outcome

Authors: Harinder Gill, Radha Raghupathy, Hsin-An Hou, Xavier Cheng-Hong Tsai, Adisak Tantiworawit, Melissa GM Ooi, Gin-Gin Gan, Chieh Lee Wong, Rita Lok Hay Yim, Lynn Chin, Paul Lee, Vivian Wing Kan Li, Lester Au, Qi Zhang, Garret M.K. Leung, Tony K.Y. Wu, Yu Yan Carmen Lee, Wee Joo Chng, Hwei-Fang Tien, Cyrus R. Kumana, Yok-Lam L Kwong

Harinder Gill: Arsenic Trioxide in newly-diagnosed Acute Promyelocytic Leukemia patients

A great collaborative effort of the APL Asian Consortium.Oral arsenic trioxide (Arsenol or SDK001), an invention of HKUMed, is the first oral formulation of ATO globally with extensive data confirming efficacy and safety.

For more updates, follow OncoDaily.

Acute promyelocytic Leukemia Arsenic Trioxide ASH Asian Consortium blood advances cancer Cyrus R. Kumana Harry Gill Hsin-An Hou Leukemia OncoDaily Oncology Promyelocytic Leukemia Radha Raghupathy Xavier Cheng-Hong Tsai Yok-Lam L Kwong
Special Coverage
Science
Dec 24, 2024, 08:02
Harinder Gill: Arsenic Trioxide in newly-diagnosed Acute Promyelocytic Leukemia patients
Science
Dec 24, 2024, 07:56
Petros Grivas: Excited to see long term follow up of our IMvigor210 trial
Blog
Dec 24, 2024, 07:48
E. Shyam P. Reddy: Aging brings two opposing trends in cancer risk
Science
Dec 24, 2024, 07:42
Serena Di Cosimo: The prognostic value of residual tumor biology during neoadjuvant treatment in patients with HER2+ breast cancer
Blog
Dec 24, 2024, 07:37
Sami (Papacek) Mansfield: All I want for the holidays is more time to move
Drugs
Dec 24, 2024, 07:26
FDA Approves Generic Nilotinib: Expanding Access to Chronic Myeloid Leukemia Treatment
Dialogues
Dec 24, 2024, 06:34
Addressing Workforce Challenges, Inequalities, and Patient-Centered Care: Insights from Isabel Rubio
Insight
Dec 24, 2024, 06:00
Impact of Cardiometabolic Syndrome on pCR And OS in Triple-Negative Breast Cancer presented at SABCS 2024
Blog
Dec 24, 2024, 00:40
Chris Boshoff: Targeted treatment regimen for mCRC with a BRAF V600E mutation
Blog
Dec 24, 2024, 00:35
Jessica Baladad: First and only AI-powered self exam app created by a breast cancer survivor
Positive
Dec 24, 2024, 00:34
Erin Cummings: I have been a cancer survivor for most of my life
Blog
Dec 24, 2024, 00:32
Amol Akhade: Physicians should accept materialistic gifts?